Icatibant Ratiopharm (Icatibant Acetate)

Icatibant acetate blocks the bradykinin B2 receptor, a key mediator of vasodilation and vascular permeability. By competitively inhibiting this receptor, the drug prevents bradykinin‑driven fluid leakage and tissue swelling, thereby halting the progression of an hereditary angioedema episode.

The dose of Icatibant Ratiopharm is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The prescriber decides the exact amount, injection volume, and timing required for each acute attack.

Safety data for icatibant acetate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting treatment.

To order Icatibant Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

The primary alternative for hereditary angioedema is plasma‑derived or recombinant C1‑inhibitor replacement therapy. While C1‑inhibitor concentrates replace the missing protein, icatibant directly blocks the bradykinin B2 receptor, offering a rapid, subcutaneous option that does not require infusion and can be administered by the patient at home.

Icatibant Ratiopharm must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold chain throughout the journey.

The medication is supplied as a sterile solution for subcutaneous injection. After proper preparation, the prescriber or patient injects the dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique and the instructions provided with the product.

Serious risks include anaphylactic or severe allergic reactions, paradoxical angioedema of the face or throat, sudden hypotension, and rare cases of injection‑site necrosis or thrombocytopenia. Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the lips or tongue, or a rapid drop in blood pressure.

Icatibant Ratiopharm should be avoided in individuals with a known hypersensitivity to icatibant acetate or any of the formulation excipients. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or those receiving ACE inhibitors or neprilysin inhibitors without close monitoring.